'Time days' diaporamas de présentation

Support from the Commonwealth Fund

Medicare Coverage of Technology, 1999-2007 How Evidence-Based, Timely, and Flexible? June 10, 2008 Peter J. Neumann, Maki S. Kamae, Jennifer A. Palmer Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA. Support from the Commonwealth Fund.

285 views • 22 slides

Risk Surveys

Risk Surveys. Lean Six Sigma Storybook. So what is a Risk Survey?. Project Charter. Problem Statement Anecdotal evidence suggested that the turnaround of Risk Surveys was up to; 10 months for new business, 12-18 months for renewals This was due to a substantial backlog.

363 views • 21 slides

Cultivar-dependent facilitation of other aphids by M. sacchari

143 views • 14 slides

Talk outline

231 views • 13 slides

Global Control of Aspergillus fumigatus Toxins

Global Control of Aspergillus fumigatus Toxins. Nancy Keller University of Wisconsin. Aspergillus secondary metabolites. Aspergillus laeA: transcriptional regulator of secondary metabolite genes. A. fumigatus. A. nidulans. ST WT ? laeA. GT WT ? laeA comp.

171 views • 13 slides

Study on HEV Vaccination Approach in Swine for Public Health protection

Study on HEV Vaccination Approach in Swine for Public Health protection. Jeanette van der Goot, Jantien Backer, Leo van Leengoed, David Rodriquez Lazaro, Franco Ruggeri, Alessandra Berto, Francesca Martelli, Ivo Pavlik, Wim H. M. van der Poel. Pig finishing farm industry. finishing farm.

227 views • 11 slides

Proppant Transport Directly Impacts Well Productivity

80. 80. Type 1 (16 Wells). Phase 1 (16 Wells). Type 2 (17 Wells). Phase 2 (17 Wells). 70. 70. Phase 3 (55 Wells). Type 3 (55 Wells). Phase 4 (120 Wells). 60. 60. Type 4 (120 Wells). Phase 5 (28 Wells). Type 5 (28 Wells). 50. 50. Rate / Net Pay (MCFD / FT).

237 views • 3 slides

F16.4.4

F16.4.4 & neg. control. OX18. OX18. 14. A. 12. OX18. 10. Mean specific fluorescence intensity. 8. 6. 4. F16.4.4. 2. 0. 0. 2. 7. 10. 12. 14. 18. 23. 25. 29. P1. P2. P3. Time (days). Neurospheres. B. CRNK. C. neg. control. F16.4.4.

90 views • 1 slides

Time (Days)

2 H ,2 H ,8 H ,8 H -PFDoA. 2 H ,8 H ,8 H -2-PFUDoA. PFBA. PFPeDiA. (a). 5. 4. Concentration ( ? M). 3. 2. 1. 0. 60. 0. 20. 40. Time (Days). PFBA. PFPeDiA. 0.10. (b). 0.08. 0.06. Concentration ( ? M). 0.04. 0.02. 0. 60. 0. 20. 40. Time (Days). Supplementary Fig. S4.

102 views • 1 slides

CTGAC

CTGAC. AACTC. AGACC. GTAAC. CTCCC. 2. 1. Cellular State. 0. -1. 21. 1. 7. 14. 21. 21. 21. 1. 7. 14. 1. 7. 14. 1. 7. 14. 21. 1. 7. 14. CGGTA. GCCCA. AGAGG. AGGGG. ACCCA. 2. 1. Cellular State. 0. -1. 21. 1. 7. 14. 21. 21. 21. 1. 7. 14. 1. 7. 14. 1.

66 views • 1 slides

Figure 1

B. PMN depletion. Control. A. PMN and macrophage depletion. PMN depletion. 100. 100. 75. 75. SURVIVAL (%). SURVIVAL (%). 50. 50. 25. 25. 0. 0. 0. 1. 2. 3. 4. 5. 0. 1. 2. 3. 4. 5. TIME (days). TIME (days). 1 x 10 6 A. fumigatus /mouse. 1 x 10 7 A. fumigatus /mouse.

83 views • 1 slides

4T1

400. 400. Tumor Volume (Rluc). Tumor Volume (Caliper). 300. 300. 200. 200. Tumor Volume (mm3). Biolum Intensity(Rluc). 100. 100. 0. 0. 0. 2. 4. 6. 8. Time (Days). 1660. 460.

120 views • 1 slides